Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as a 30 mg oral tablet for oral use. It is used for prevention of cerebral vasospasm following subarachnoid hemorrhage in patients at risk.

GNH USA supplies Nimotop as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is employed in the management of cerebral vasospasm, a vascular complication following subarachnoid hemorrhage.

- Subarachnoid hemorrhage: prevention of cerebral vasospasm - Delayed ischemic neurological deficit: reduction of incidence after SAH - Cerebral blood flow impairment: improvement of perfusion following SAH

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity - Dizziness or light‑headedness: especially on standing - Flushing or warmth sensation: transient - Nausea or abdominal discomfort: occasional

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention - Bradycardia or heart block: monitor cardiac rhythm - Hepatic dysfunction: elevated liver enzymes - Allergic reactions: rash, pruritus, or angioedema - Rare skin disorders: Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating Nimodipine therapy, clinicians should consider several safety measures.

- Monitor blood pressure: watch for symptomatic hypotension - Assess hepatic function: adjust use if liver impairment is present - Avoid strong CYP3A4 inhibitors: may increase drug exposure - Use caution in elderly patients: increased sensitivity to hemodynamic changes - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nimodipine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxicity - Concomitant antihypertensives: additive hypotensive effect

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy - Grapefruit juice: can increase plasma concentrations - Other calcium‑channel blockers: may enhance cardiovascular effects